1st Mar 2005 07:00
1 March 2005 Tepnel Life Sciences PLC COMPANY STRATEGY Briefing, March 22nd2005 Advance notice of Preliminary Results Manchester, UK. 1 March 2005¢â‚¬¦ The Board of Tepnel Life Sciences' (AIM: TED) arepleased to invite investors to their Company Strategy Briefing to be held on22nd March 2005 from 11am - 12:30pm.Venue: New Connaught Rooms, Covent Garden Exhibition Centre, 61-65 Great QueenStreet, London, WC2B 5DADuring this briefing the Company will present its preliminary results for yearended 31 December 2004 together with a presentation on strategy and directionfor the future.Any investor who would like to attend should contact:Elni Stofberg, De Facto Communications (tel: +44 (0)207 940 1022), e-mail:[email protected] -ends- For Further Information:Tepnel Life Sciences plcBen Matzilevich, CEOGron Ffoulkes-Davies, Finance Director0161 946 2200Seymour PierceMark Percy, Corporate Finance0207 107 8000De Facto CommunicationsRichard Anderson020 7940 1000Notes to EditorsAbout Tepnel Life Sciences plcTepnel is a UK-based international life sciences instrumentation and servicescompany with a `tri-polar' strategy focused on providing the biomedicalindustry with high-throughput automated DNA purification systems, manual DNApurification kits and reagents, as well as scientific services for nucleic acidpurification, drug analysis, genotyping and genetically modified foods. Tepnelwas founded in 1992 to exploit DNA technology generated at UMIST (University ofManchester Institute of Science and Technology) and is quoted on the AIMsegment of the London Stock Exchange (AIM: TED). More information on Tepnel canbe found at www.tepnel.com.ENDRelated Shares:
TED.L